arrow
B

Bhavneet Bhinder

Caryl and Israel Englander Institute for Precision Medicine
H指数:28
被引数:3,069

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Role of orphan G protein-coupled receptor GPR52 in breast cancer cell multicellular organization and collective invasion

孤核G蛋白偶联受体GPR52在乳腺癌细胞多细胞组织形成和集体侵袭中的作用

2026-08-200
OAAI
Patient-derived organoids across cancers reveal conserved tumor heterogeneity and actionable therapeutic vulnerabilities

患者来源的类器官跨越癌症揭示了保守的肿瘤异质性和可操作的药物治疗易感性

2026-06-260
OA
Tumor immune microenvironment reconstitution in patient-derived organoids enables therapy modeling for NSCLC

患者来源类器官中的肿瘤免疫微环境重建实现了非小细胞肺癌的治疗建模

2026-05-130
OAAI
Secretory kinase FAM20C triggers adipocyte dysfunction, inciting insulin resistance and inflammation in obesity

分泌型激酶FAM20C触发脂肪细胞功能障碍,引发肥胖中的胰岛素抵抗和炎症

2026-01-021
OA
MRD-driven Initial Therapy of Acalabrutinib and Lenalidomide plus Rituximab (ALR) or Obinutuzumab (ALO) for Mantle Cell Lymphoma

微小残留病驱动的阿卡替尼联合来那度胺与利妥昔单抗(ALR)或奥比妥珠单抗(ALO)初始治疗套细胞淋巴瘤

2025-11-270
OAAI
Integrative transcriptomic and single-cell protein characterization of colorectal carcinoma delineates distinct tumor immune microenvironments associated with overall survival

整合转录组学和单细胞蛋白质表征的结直肠癌研究,阐明了与总生存期相关的不同肿瘤免疫微环境。

2025-07-280
PRE
MRD-Driven Time-Limited Therapy of Acalabrutinib and Lenalidomide Plus Rituximab (ALR) or Obinutuzumab (ALO) in Patients with Treatment-Naive Mantle Cell Lymphoma: Phase 2 Trial Outcomes with MRD and cfDNA Analyses

MRD驱动的有限疗程Acalabrutinib联合Lenalidomide和Rituximab(ALR)或Obinutuzumab(ALO)治疗初治套细胞淋巴瘤患者的疗效:含MRD和cfDNA分析的II期试验结果

BLOOD
IF23.1
2024-11-051
PRE
The evolution of metastatic upper tract urothelial carcinoma through genomic-transcriptomic and single-cell protein markers analysis
2024-03-181
OAAI
Cysteine induces mitochondrial reductive stress in glioblastoma through hydrogen peroxide production

半胱氨酸通过产生过氧化氢诱导胶质母细胞瘤线粒体还原应激

2024-02-155
OAAI
Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial (vol 19, 8435, 2023)
2024-01-030
OAAI
Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial
2023-12-1913
OAAI
Molecular Evolution of Classic Hodgkin Lymphoma Revealed Through Whole-Genome Sequencing of Hodgkin and Reed Cells
2023-01-3118
OA